Bluebird Bio Upgraded At Morgan Stanley; Firm Sees 'Innovation At A Discount'

By: via Benzinga
bluebird bio Inc (NASDAQ: BLUE) shares are down 42 percent in the last three months and are trading significantly below their ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.